MRK
MRNA
The rally was real — and then the market took a breath
Moderna didn’t exactly sneak into Wednesday. The stock exploded intraday, then gave some of it back after hours once the caffeine wore off. The driver: positive Phase 3 results from the INTerpath-001 trial for intismeran autogene, Moderna and Merck’s individualized mRNA-based cancer therapy.
Why this matters
This wasn’t just another biotech headline with a lot of syllables. The combo of intismeran autogene and Merck’s KEYTRUDA beat KEYTRUDA alone on recurrence-free survival and distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma.
A few things make investors perk up here:
- It’s the first positive Phase 3 result for an individualized neoantigen therapy
- It’s also the first positive Phase 3 result for an mRNA-based cancer therapy
- The trial enrolled 1,137 patients, so this isn’t some tiny science fair project
The Merck-Moderna tag team
Think of this like a movie sequel where the sidekick matters. Merck isn’t just a name in the press release — it co-developed the therapy with Moderna, and KEYTRUDA is already a blockbuster in its own right. So when the combo starts looking better than KEYTRUDA alone, the market immediately starts pricing in a bigger oncology opportunity.
The ripple effect
That’s why BioNTech, Tempus AI, CRISPR Therapeutics, and Pfizer all showed up in the after-hours chatter too. They’re not all directly involved in this trial, but they live somewhere in the same biotech neighborhood — and when one house lights up like this, everyone else’s porch light gets checked.
Big picture: Moderna just got a rare kind of biotech headline — the kind that can turn “promising platform” into “show me the commercial roadmap.” That doesn’t guarantee a straight line higher, but it does give investors a lot more reason to keep watching the mRNA cancer story.